Article Sidebar
Views PDF: 192
RESEARCH OF THE CONCENTRATION OF DOPAMINE AND ITS METABOLITES IN THE CEREBROSPINAL FLUID AND ITS RELATIONSHIP WITH SOME CLINICAL MANIFESTATIONS IN PATIENTS WITH PARKINSON'S DISEASE
Main Article Content
Abstract
Objectives: To study the concentration of dopamine and its metabolites (DOPAC) in the cerebrospinal fluid (CSF) and its relationship with some clinical manifestations in patients with Parkinson's disease. Subjects and methods: Prospective, cross-sectional description with comparison with control group. Sampling method: Convenience sampling. Quantitative testing of dopamine and DOPAC levels of cerebrospinal fluid for both disease and control groups. Results: The mean concentration of dopamine in the control group was 31.85 ± 12.56 pg/ml while in the Parkinson's group it was 20.10 ± 3.52 pg/ml. The mean DOPAC concentration of CSF in the control group was 7.03 ± 4.14 ng/ml while in Parkinson's patients it was 3.75 ± 3.00 pg/ml. The concentration of dopamine, DOPAC of cerebrospinal fluid gradually decreased from stage 1 to stage 4.5. The difference is statistically significant (p<0.001). The concentration of dopamine and DOPAC in the cerebrospinal fluid gradually decreased from mild disease to severe and very severe disease. The difference is statistically significant (p<0.001). Dopamine levels, CSF DOPAC gradually decreased from no depression to mild, moderate and severe depression. The difference is statistically significant (p<0.05). There was a statistically significant negative correlation between the concentration of dopamine in the cerebrospinal fluid and the duration of the disease (R = -0.764, p<0.001). There was a statistically significant negative correlation between the CSF DOPAC concentration and the duration of the disease (R = -0.690, p<0.001). Conclusion: Our study showed that there was a significant decrease in the concentration of dopamine, CSF DOPAC in Parkinson's patients compared with the control group, the more severe the disease, the more advanced the disease stage, the concentration of dopamine, DOPAC in cerebrospinal fluid. marrow decreases. There is a statistically significant negative correlation between the concentration of dopamine, DOPAC of cerebrospinal fluid and the duration of the disease.
Article Details
Keywords
Parkinson's disease, CSF dopamine concentration, CSF DOPAC concentration
References
2. Fahn S., Sulzer D. Neurodegeneration and neuroprotection in Parkinson disease. NeuroRx. 2004;1(1):139–154.
3. El-Agnaf O.M.A, Salem S.A, Paleologou K.E, et al. Detection of oligomeric forms of (-synuclein protein in human plasma as a potential biomarker for Parkinson’s disease. FASEB J. 2006; 20: 419–425.
4. Fearnley J.M, Lees A.J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain. 1991; 114:2283–2301.
5. Bisaglia M., Filograna R., Beltramini M., et al. Are dopamin derivatives implicated in the pathogenesis of Parkinson’s disease? Ageing Research Reviews. 2014; 13:107-114.
6. Hoàng Thị Dung (2014), Nghiên cứu đặc điểm lâm sàng và định lượng nồng độ Dopamin huyết tương ở bệnh nhân Parkinson, Luận văn thạc sỹ Y học, Học viện Quân Y, Hà Nội.
7. Nguyễn Đức Thuận, Lê Văn Quân, và Nhữ Đình Sơn (2020). Thay đổi nồng độ Dopamin huyết tương trên bệnh nhân Parkinson. Tạp chí Y dược học quân sự, 2, 116–121.
8. Eldrup E., Mogensen P., Jacobsen J., et al. CSF and Plasma Concentrations of Free Norepinephrine, Dopamin, 3,4-dihydroxyphenylacetic Acid (DOPAC), 3,4-dihydroxyphenylalanine (DOPA), and Epinephrine in Parkinson's Disease. Acta Neurol Scand. 1995; 92(2):116-21.
9. Goldstein S., Holmes C., Sharabi Y. Cerebrospinal fluid biomarkers of central catecholamine deficiency in Parkinson’s disease and other synucleinopathies. Brain, 2012; 135(6): 1900–1913.
10. Functional and Streotactic Neurology Staging of Parkinson’s Disease. MGH Neurosugical Service 1999.